company profile a fast growing, fully integrated, research oriented pharmaceutical company with a...
TRANSCRIPT
Corporate Presentation
Indoco Remedies Ltd
Company ProfileA fast growing, fully integrated, research oriented pharmaceutical company
with a Global presence
Revenues in FY 2013-14 `7277 Mn (US $ 121 Mn)
Domestic business contributes 64% and international business contributes 36% of the revenues
Formulation business contributes 93% and API business contributes 7% of revenues
Workforce of over 4500
- 200 R&D scientists
- 2300 field staff
Our Infrastructure
Corporate Office at Santacruz (E), Mumbai
8 Manufacturing Facilities - 5 FDFs - 3 APIs
R&D Centre at Navi Mumbai
29 C&Fs
Mfg. Facilities for FDFs LOCATIO
NDOSAGE FORM APPROVALS
GOA ITABLETS, CREAMS
& OINTMENTS
US-FDA, EU-GMP, TGA Australia,
MCC South Africa,ANVISA - Brazil
GOA IISTERILE
PRODUCTS
US-FDA, EU-GMP, MCC South Africa,
TGA Australia
GOA III TABLETSUS-FDA, EU-GMP, TGA Australia,
WALUJ TABLETS Emerging Markets
BADDITABLETS, LIQUID
ORALS & TOOTHPASTES
EU–GMP and Emerging Markets
API facilities Multi-ton : Patalganga (USFDA , TGA Australia
approved)
- Reactor Capacity: 500 to 5000 L
Kilo Scale: Navi Mumbai (USFDA , TGA Australia approved)
- Reaction Systems: 16 to 500 L - Total Reactor Volume: 1 cubic meters - Temperatures range: -55 to + 150 celsius
Intermediates : Rabale
- Reactor Capacity: 500 to 3000 L - Total Reactor Volume: 50 cubic meters
Research & Development
US $ 10 Mn Investment in R&D set-up
Spread over an area of 150,000 square feet and employs over 200 scientists and technical personnel
58 Patents filed - 38 for APIs - 20 for FDFs
Business Model
• Branded Generics - 8 Marketing Divisions - 18 Therapeutic Segments - 150 Brands
• APIs
• Regulated Markets - Generic Business - CRAMS - Alliances
• Emerging Markets - Branded Generics - Through Distributors - Alliance
INTERNATIONAL BUSINESS
(Covers 80 countries)
INDIAN BUSINESS
Ranked 27th by CMARC in Rx Ranking Ranked 28th by AWACS in SSA Audit (Sept’14)
8 MARKETING DIVISIONS
INDOCO GPs, CPs, Gynaec, Pediatrician
SPADE GPs, CPs, Pediatrician, ENTs, Otologicals
WARREN Dental
EXCEL Opthalmic
SPERA GPs, Gynaec, Pediatrician
ETERNA CPs, Orthos, Gastro
INDOCO CND
Lifestyle / Cardio & Diabetology
INSTITUTION
Caters to Hospital & Government Supplies
Indian Business
Growth Drivers (Domestic Business)
Growing middle class population, increasing income levels, rapid urbanization, demand for quality healthcare services & changing lifestyle
Focus on chronic segment
Penetration in Northern and Eastern Regions
New Products introductions (around 20 products every year)
Growth above Industry Average
International Business
Revenue of
Rs. 2005 Mn in FY14
(US $ 33 Mn)
Revenue contribution
UK 48%, USA 23 %,
SA 12%, Germany 8%)
CRAMS,
Dossier Out-Licensing,
Out-Licensing of MAs
Actavis (Watson) Partnership
Regulated Markets
(85% of
Formulation
Export Business)
Revenue of
Rs. 307 Mn in FY14
(US $ 5 Mn)
Revenue contribution
Africa 8%, Asia 2%,
Latam 2%
Promotion of Branded
Generics through
Distributors
Aspen Partnership
Emerging Markets
(15% of
Formulation
Export Business)
Strong Partnership with Watson Pharmaceuticals Inc., USA
Multi-product, Multi-territory alliance with Aspen Pharmacare, SA
Own filing of ANDAs and Dossiers
NDDS and new technology platforms
Growth Drivers (International Business)
Segment wise Break-up and Contribution
68%
27%
5%
2008-09
61%
32%
6%
2013-14
91%
7% 2%
2003-04
(` In Lacs) Profit & Loss A/C – Percentage to Net Sales
Particulars
Quarter Ended Half Year Ended Year Ended
31.03.14
(Audited)
% to Sales 30.09.14
(Unaudited) % to Sales
30.09.13 (Unaudited)
% to Sales
30.09.14 (Unaudited)
% to Sales
30.09.13 (Unaudited)
% to Sales
INCOME Net Sales / Income from Operations 22642 19505 42437 34310
71737 Add: Other Operating Income 201 726 269 1318 1034 Total Income from Operations 22843 20231 42706 35628 72771
Add: Other Income 56 46 118 62 175 Total Income 22899 20277 42824 35690 72946 EXPENDITURE Material Cost 7971 35.2 7576 38.8 15228 35.9 13545 39.5 26916 37.5
Employees Benefit Expenses 3596 15.9 3338 17.1 6970 16.4 6221 18.1 12905 18.0
Research & Development Expenses 489 2.2 384 2.0 918 2.2 658 1.9 1443 2.0
Other Expenses 5924 26.2 5635 28.9 11070 26.1 9468 27.6 19500 27.2
Finance Cost 268 1.2 527 2.7 541 1.3 1149 3.3 1880 2.6
Depreciation and Amortisation Expenses 1315 5.8 772 4.0 2262 5.3 1505 4.4 3091 4.3
Misc. Expenditure Written Off. - - - - - - - 1 - Total Expenses 19563 18232 36989 32546 65735 PBT 3336 14.7 2045 10.5 5835 13.7 3144 9.2 7211 10.1
Tax Expenses 1095 441 1590 622 1421 PAT 2241 9.9 1604 8.2 4245 10.0 2522 7.4 5790 8.1
EBIDTA (w/o R&D) 5352 23.6 3682 18.9 9438 22.2 6394 18.6 13451 18.8
EBIDTA (with R&D) 4863 21.5 3298 16.9 8520 20.1 5736 16.7 12008 16.7
Operating Profit 3769 16.7 2383 12.2 6635 15.6 3740 10.9 8479 11.8